Navigation Links
Boston Heart Lab Named 'Most Promising Early Stage Company' 2009 by Silicom Ventures
Date:6/29/2009

FRAMINGHAM, Mass., June 29 /PRNewswire/ -- Boston Heart Lab, a pioneer in specialized diagnostics for patients with heart disease, was named "Most Promising Early Stage Company" by Silicom Ventures at the angel investment organization's 2009 Investment Summit, which took place June 2-3, 2009, at Stanford University in California. A four-judge panel selected Boston Heart Lab after evaluating the 20 participating companies for quality of management, vision, execution abilities, and the potential scope of the opportunities. Boston Heart Lab Chief Executive Officer, Wolfgang Daum, Ph.D., accepted the award on behalf of the start-up company, which has seen strong revenues since it began clinical operations in August 2008.

"We're very honored to receive this prestigious award, which is a testament both to the important work our Boston Heart Lab team has done to develop and launch our advanced cardiovascular diagnostic and lipid-testing program, and to the relevance of the services we provide to the marketplace," said Dr. Daum. "While there are other providers of esoteric testing for cardiology, we employ the most-advanced technology available with our proprietary two-dimensional gel electrophoresis of HDL particles and plasma sterol analysis. We deliver clinicians a more complete picture of the patient's health status -- our test results and analyses are the critical building blocks for a personalized treatment plan designed to offer patients the best opportunity for improved health outcomes. This includes more than 35 proprietary tests to assess the patient's cardiac health and risk profile, and a treatment algorithm (Boston Heart Navigator) based on the latest peer-reviewed scientific data."

Commenting on the award, Silicom Ventures' Founder and Managing Director, Gadi Behar, said, "The 2009 Investment Summit showcased 20 impressive early-stage companies in various fields -- from alternative energy and social networkin
'/>"/>

SOURCE Boston Heart Lab
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Boston Cardinal OMalley Withdraws Caritas Christi From Potential Abortion Scandal
2. Boston Scientific Announces Retirement of Jim Tobin and Appointment of Ray Elliott as New President and CEO
3. Childrens Hospital Boston, CompuCyte Corporation Establish International Quantitative Imaging Cytometry Center
4. American Life League: Revelations in Boston Archdiocese Caritas Scandal
5. Greater Boston unites to transform health care
6. Boston Scientifics Urology/Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting
7. Fifth Annual Games for Health Conference Kicks Off in Boston
8. Clock Ticking In Boston Archdiocese Abortion Scandal
9. Boston Medical Center Selects Bank of America to Assist with Payments Transformation
10. NYP/Weill Cornell physician-scientists present at 2009 American Transplant Congress in Boston
11. Boston Scientific Announces Two Directors Leave Board as Burns Named CEO of Xerox and Johnson Confirmed as Under Secretary of Energy
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Millions Flowing into Medical Real Estate 13292 1Millions Flowing into Medical Real Estate 13292 2Millions Flowing into Medical Real Estate 13292 3Insurance Department Releases Report on Executive Compensation at States Largest Blues Plans 53231 1Insurance Department Releases Report on Executive Compensation at States Largest Blues Plans 53231 2